Medscape is available in 5 Language Editions – Choose your Edition here.


C-11 Hydroxylase Deficiency

  • Author: Gabriel I Uwaifo, MD; Chief Editor: George T Griffing, MD  more...
Updated: Sep 06, 2013


Congenital adrenal hyperplasia (CAH) is a general term used to describe a group of inherited disorders in which a defect in cortisol biosynthesis is present with consequent overproduction of adrenocorticotropic hormone (ACTH) and secondary adrenal hyperplasia as a consequence. An enzymatic defect in 11-beta-hydroxylase is the second most common variant of CAH and accounts for approximately 5-8% of cases.

Patients with 11-beta-hydroxylase deficiency present with features of androgen excess, including masculinization of female newborns and precocious puberty in male children. Approximately two thirds of patients also have hypertension, which may or may not be associated with mineralocorticoid excess, hypokalemia, and metabolic alkalosis. The association of CAH with hypertension was first noted in the 1950s. The hypertension is initially responsive to glucocorticoid replacement, but it may become a chronic condition subsequently requiring standard antihypertensive therapy.



The zona fasciculata normally secretes cortisol, predominantly under the trophic effect of ACTH. The steroid biosynthetic pathway is shown in the image below. Knowledge of this pathway is vital to understanding the clinical presentation of 11-beta-hydroxylase deficiency and the other variants of congenital adrenal hyperplasia (CAH). See the image below.

Steroidogenesis pathways in the adrenal cortex. Steroidogenesis pathways in the adrenal cortex.

In the zona fasciculata, the typical end product of the steroid biosynthetic pathway is cortisol, as shown in the image above, and cortisol regulates pituitary ACTH production through negative feedback inhibition. Loss of 11-beta-hydroxylase activity in the adrenal gland blocks the synthesis of cortisol and results in an increase in ACTH production. Aldosterone is the main mineralocorticoid produced by the adrenal zona glomerulosa, and its production is regulated by the renin-angiotensin system. A 17-hydroxy pathway similar to the active pathway in the zona glomerulosa exists in the zona fasciculata; however, the final product is corticosterone rather than aldosterone. Corticosterone is hydroxylated and oxidized at the 18 position to produce aldosterone in the glomerulosa, but not in the fasciculata.

The adrenal fasciculata production of corticosterone, a weak glucocorticoid, and deoxycorticosterone (DOC), a potent mineralocorticoid, is minimal and relatively unimportant in healthy normal individuals, but it is important in patients with 11-beta-hydroxylase deficiency. In these patients, a new steady state is achieved and excess DOC production occurs due to elevated ACTH levels.

Humans have two 11-beta-hydroxylase isoenzymes that are 93% identical. CYP11B1 is responsible for cortisol biosynthesis; it is expressed in the zona fasciculata and is regulated by ACTH. CYP11B2, which is responsible for aldosterone synthesis, is expressed in the zona glomerulosa and is regulated by the renin-angiotensin system and by potassium levels.[1] The genetic elements responsible for the differential regulation of CYP11B1 and CYP11B2 have not been elucidated completely. CAH due to 11-hydroxylase deficiency is due to genetic defects of CYP11B1 characterized by impaired conversion of 11-deoxycortisol to cortisol, reduced cortisol, impaired conversion of DOC to corticosterone, and increased 11-deoxycortisol, DOC, and ACTH secretion.[2, 3, 4]

Mutations of the CYP11B2 gene cause aldosterone deficiency with characteristic features of mineralocorticoid deficiency.[5] No associated cortisol deficiency or consequent adrenal hyperplasia is present, and isolated aldosterone synthetase deficiency is not a type of CAH.

Patients with 11-beta-hydroxylase deficiency have clinical features of androgen excess, such as premature sexual maturation observed in boys and virilization in females. These symptoms are the result of excess adrenal androgen production and are similar to those observed in the more common virilizing form of CAH, 21-hydroxylase deficiency. Accumulated cortisol precursors are shunted into the pathway of adrenal androgen production, as shown in the image above. Affected girls are born with some degree of virilization of their external genitalia, while the internal genital structures derived from the müllerian ducts (fallopian tubes, uterus, and cervix) are unaffected. Postnatally, both sexes may experience rapid somatic growth, accelerated skeletal maturation and premature development of sexual and body hair. Affected boys present with premature sexual maturation.

About two-thirds of patients with the severe (classic) variant of 11-beta-hydroxylase deficiency have early onset hypertension.[6] This hypertension generally is mild to moderate, but in as many as one third of cases, it is associated ultimately with left ventricular hypertrophy, retinopathy, and macrovascular events. The exact cause of the hypertension is unclear and is presumed to be due to excessive secretion of DOC, a mineralocorticoid. Overall however, the degree of DOC excess does not correlate with the degree or severity of hypertension. Possibly, the 18-hydroxy and the 19-nor metabolites of DOC, which are mineralocorticoids, may play an additional role.

Rarely, patients with 11-beta-hydroxylase deficiency may have salt wasting, especially during infancy. The exact pathophysiology of this is unclear. In some cases, excess glucocorticoid administration appears to play a role through suppression of DOC secretion. If the zona glomerulosa is chronically suppressed by excess DOC, a sudden decrease in DOC associated with glucocorticoid therapy may not be compensated for by an adequate increase in aldosterone secretion. In cases that have been described prior to beginning therapy with glucocorticoids, the suggested mechanisms include abnormal sensitivity to the natriuretic effects of various putative natriuretic factors.

A milder, late-onset (nonclassic) form of CYP11B1 deficiency with symptoms of androgen excess is rare, but it has been described. Patients with this condition are not hypertensive. It is not a significant cause of hyperandrogenism in women, and stringent criteria should be used for diagnosis. ACTH-stimulated levels of 11-deoxycortisol should be at least 5 times the upper limit of normal levels to establish the diagnosis of nonclassic 11-beta-hydroxylase deficiency.




United States

The prevalence of 11-beta-hydroxylase deficiency is approximately 1 case per 100,000 live births.


The international prevalence of 11-beta-hydroxylase deficiency is similar to US rates in most reported series worldwide. However, the reported rate in Jews from Morocco is much higher, being 1 case per 5000-7000 live births.[7]


The classic hypertensive variants of 11-beta-hydroxylase deficiency have the greatest potential for long-term morbidity.


11-beta-hydroxylase deficiency is most commonly found in Jewish people of Moroccan descent.[7]


Although 11-beta-hydroxylase deficiency is more easily recognizable in females, no sex predilection exists.


A genetic disease, 11-beta-hydroxylase deficiency affects patients throughout their life.

  • The peak age at diagnosis is infancy and early childhood. Females present as neonates with ambiguous external genitalia, and males present as toddlers with virilization.
  • The mild form of 11-beta-hydroxylase deficiency is rare and may present with menstrual irregularities and hirsutism in adolescent or adult women. [8]
Contributor Information and Disclosures

Gabriel I Uwaifo, MD Associate Professor, Section of Endocrinology, Diabetes and Metabolism, Louisiana State University School of Medicine in New Orleans; Adjunct Professor, Joint Program on Diabetes, Endocrinology and Metabolism, Pennington Biomedical Research Center in Baton Rouge

Gabriel I Uwaifo, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Medical Association, American Society of Hypertension, Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Arthur B Chausmer, MD, PhD, FACP, FACE, FACN, CNS Professor of Medicine (Endocrinology, Adj), Johns Hopkins School of Medicine; Affiliate Research Professor, Bioinformatics and Computational Biology Program, School of Computational Sciences, George Mason University; Principal, C/A Informatics, LLC

Arthur B Chausmer, MD, PhD, FACP, FACE, FACN, CNS is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Nutrition, American Society for Bone and Mineral Research, International Society for Clinical Densitometry, American College of Endocrinology, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Informatics Association, Endocrine Society

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, International Society for Clinical Densitometry, Southern Society for Clinical Investigation, American College of Medical Practice Executives, American Association for Physician Leadership, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society

Disclosure: Nothing to disclose.

Additional Contributors

Ghassem Pourmotabbed, MD, MD 

Ghassem Pourmotabbed, MD, MD is a member of the following medical societies: American Diabetes Association, American Federation for Medical Research, Endocrine Society

Disclosure: Nothing to disclose.


Deborah P Merke, MD, Chief of Pediatric Services, Pediatric and Reproductive Endocrinology Branch, Warren Grant Magnuson Clinical Center; Clinical Investigator, National Institute of Child Health and Human Development, contributed to this article.

  1. Mornet E, Dupont J, Vitek A. Characterization of two genes encoding human steroid 11 beta- hydroxylase (P-450(11) beta). J Biol Chem. 1989 Dec 15. 264(35):20961-7. [Medline]. [Full Text].

  2. Joehrer K, Geley S, Strasser-Wozak EM. CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Hum Mol Genet. 1997 Oct. 6(11):1829-34. [Medline]. [Full Text].

  3. Zhu YS, Cordero JJ, Can S, et al. Mutations in CYP11B1 gene: phenotype-genotype correlations. Am J Med Genet A. 2003 Oct 15. 122(3):193-200. [Medline].

  4. Xu C, Qiao J, Liu W, Jiang X, Yan F, Wu J, et al. Identification and functional characterization of a large deletion of the CYP11B1 gene causing an 11ß-Hydroxylase deficiency in a Chinese pedigree. Horm Res Paediatr. 2012. 78(4):212-7. [Medline].

  5. Pascoe L, Curnow KM, Slutsker L. Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci U S A. 1992 Jun 1. 89(11):4996-5000. [Medline]. [Full Text].

  6. Davies E, Mackenzie SM, Freel EM, et al. Altered corticosteroid biosynthesis in essential hypertension: a digenic phenomenon. Mol Cell Endocrinol. 2008 Sep 19. [Medline].

  7. Rosler A, Leiberman E, Cohen T. High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco. Am J Med Genet. 1992 Apr 1. 42(6):827-34. [Medline].

  8. Reisch N, Högler W, Parajes S, Rose IT, Dhir V, Götzinger J, et al. A diagnosis not to be missed: Non-classic steroid 11ß-hydroxylase deficiency presenting with premature adrenarche and hirsutism. J Clin Endocrinol Metab. 2013 Aug 12. [Medline].

  9. Storr HL, Barwick TD, Snodgrass GA, et al. Hyperplasia of adrenal rest tissue causing a retroperitoneal mass in a child with 11 beta-hydroxylase deficiency. Horm Res. 2003. 60(2):99-102. [Medline].

  10. Peter M, Janzen N, Sander S, et al. A case of 11beta-hydroxylase deficiency detected in a newborn screening program by second-tier LC-MS/MS. Horm Res. 2008. 69(4):253-6. [Medline].

  11. Christakoudi S, Cowan DA, Taylor NF. Steroids excreted in urine by neonates with 21-hydroxylase deficiency. 3. Characterization, using GC-MS and GC-MS/MS, of androstanes and androstenes. Steroids. 2012 Nov. 77(13):1487-501. [Medline].

  12. Carlson AD, Obeid JS, Kanellopoulou N. Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment. J Steroid Biochem Mol Biol. 1999 Apr-Jun. 69(1-6):19-29. [Medline].

  13. Cerame BI, Newfield RS, Pascoe L, et al. Prenatal diagnosis and treatment of 11beta-hydroxylase deficiency congenital adrenal hyperplasia resulting in normal female genitalia. J Clin Endocrinol Metab. 1999 Sep. 84(9):3129-34. [Medline]. [Full Text].

  14. Rosler A, Leiberman E, Rosenmann A, et al. Prenatal diagnosis of 11beta-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1979 Oct. 49(4):546-51. [Medline].

  15. Van Vliet G, Polak M, Ritzén EM. Treating fetal thyroid and adrenal disorders through the mother. Nat Clin Pract Endocrinol Metab. 2008 Dec. 4(12):675-82. [Medline].

  16. German A, Suraiya S, Tenenbaum-Rakover Y, et al. Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. J Clin Endocrinol Metab. 2008 Dec. 93(12):4707-10. [Medline].

  17. Mantero F, Opocher G, Rocco S. Long-term treatment of mineralocorticoid excess syndromes. Steroids. 1995 Jan. 60(1):81-6. [Medline].

  18. Garner PR. Congenital adrenal hyperplasia in pregnancy. Semin Perinatol. 1998 Dec. 22(6):446-56. [Medline].

  19. Meyer-Bahlburg HF. What causes low rates of child-bearing in congenital adrenal hyperplasia?. J Clin Endocrinol Metab. 1999 Jun. 84(6):1844-7. [Medline]. [Full Text].

  20. Burgu B, Duffy PG, Cuckow P, et al. Long-term outcome of vaginal reconstruction: comparing techniques and timing. J Pediatr Urol. 2007 Aug. 3(4):316-20. [Medline].

  21. Azziz R. Nonclassic adrenal hyperplasia. Bardin CW, ed. Current Therapy in Endocrinology and Metabolism. 6th ed. St Louis, Mo: Mosby-Yearbook; 1997. 175-8.

  22. Azziz R, Boots LR, Parker CR Jr. 11 beta-hydroxylase deficiency in hyperandrogenism. Fertil Steril. 1991 Apr. 55(4):733-41. [Medline].

  23. Cathelineau G, Brerault JL, Fiet J, et al. Adrenocortical 11 beta-hydroxylation defect in adult women with postmenarchial onset of symptoms. J Clin Endocrinol Metab. 1980 Aug. 51(2):287-91. [Medline].

  24. Deaton MA, Glorioso JE, McLean DB. Congenital adrenal hyperplasia: not really a zebra [published erratum appears in Am Fam Physician 1999 Sep 15;60(4):1107]. Am Fam Physician. 1999 Mar 1. 59(5):1190-6, 1172. [Medline]. [Full Text].

  25. Ghazi AA, Hadayegh F, Khakpour G, et al. Bilateral testicular enlargement due to adrenal remnant in a patient with C11 hydroxylase deficiency congenital adrenal hyperplasia. J Endocrinol Invest. 2003 Jan. 26(1):84-7. [Medline].

  26. Kalaitzoglou G, New MI. Congenital adrenal hyperplasia. Molecular insights learned from patients. Receptor. 1993 Fall. 3(3):211-22. [Medline].

  27. Lucky AW, Rosenfield RL, McGuire J, et al. Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab. 1986 May. 62(5):840-8. [Medline].

  28. Mantero F, Opocher G, Armanini D. 11 Beta-hydroxylase deficiency. J Endocrinol Invest. 1995 Jul-Aug. 18(7):545-9. [Medline].

  29. Merke DP, Tajima T, Chhabra A. Novel CYP11B1 mutations in congenital adrenal hyperplasia due to steroid 11 beta-hydroxylase deficiency. J Clin Endocrinol Metab. 1998 Jan. 83(1):270-3. [Medline]. [Full Text].

  30. Miller WL. Congenital adrenal hyperplasia in the adult patient. Adv Intern Med. 1999. 44:155-73. [Medline].

  31. Miller WL. Early steps in androgen biosynthesis: from cholesterol to DHEA. Baillieres Clin Endocrinol Metab. 1998 Apr. 12(1):67-81. [Medline].

  32. Moran C, Knochenhauer ES, Azziz R. Non-classic adrenal hyperplasia in hyperandrogenism: a reappraisal. J Endocrinol Invest. 1998 Nov. 21(10):707-20. [Medline].

  33. New MI, Newfield RS. Congenital adrenal hyperplasia. Bardin CW, ed. Current Therapy in Endocrinology and Metabolism. 6th ed. St Louis, Mo: Mosby-Yearbook; 1997. 179-187.

  34. Pang S. Congenital adrenal hyperplasia. Baillieres Clin Obstet Gynaecol. 1997 Jun. 11(2):281-306. [Medline].

  35. Pang S, Levine LS, Lorenzen F. Hormonal studies in obligate heterozygotes and siblings of patients with 11 beta-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1980 Mar. 50(3):586-9. [Medline].

  36. Panitsa-Faflia C, Batrinos ML. Late-onset congenital adrenal hyperplasia. Ann N Y Acad Sci. 1997 Jun 17. 816:230-4. [Medline].

  37. Stratakis CA, Rennert OM. Congenital adrenal hyperplasia: molecular genetics and alternative approaches to treatment. Crit Rev Clin Lab Sci. 1999 Aug. 36(4):329-63. [Medline].

  38. White PC. Genetic diseases of steroid metabolism. Vitam Horm. 1994. 49:131-95. [Medline].

  39. White PC. Steroid 11 beta-hydroxylase deficiency and related disorders. Endocrinol Metab Clin North Am. 2001 Mar. 30(1):61-79, vi. [Medline].

  40. White PC, Curnow KM, Pascoe L. Disorders of steroid 11 beta-hydroxylase isozymes. Endocr Rev. 1994 Aug. 15(4):421-38. [Medline].

  41. White PC, Obeid J, Agarwal AK. Genetic analysis of 11 beta-hydroxysteroid dehydrogenase. Steroids. 1994 Feb. 59(2):111-5. [Medline].

  42. White PC, Speiser PW. Steroid 11 beta-hydroxylase deficiency and related disorders. Endocrinol Metab Clin North Am. 1994 Jun. 23(2):325-39. [Medline].

  43. Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. J Clin Endocrinol Metab. 1983 Feb. 56(2):222-9. [Medline].

Steroidogenesis pathways in the adrenal cortex.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.